Cencora reported mixed fiscal first-quarter 2026 results, including a revenue miss despite slightly exceeding adjusted EPS expectations. The company's guidance tweak is contributing to share price pressure.
Cencora Reports Mixed Q1 2026 Results With Revenue Miss, Guidance Tweak
CORPharmaceuticalsHealthcareEarnings MissGuidanceShare Price

